Read by QxMD icon Read

'Multiple Sclerosis'

Tibor Hortobágyi, Azusa Uematsu, Lianne Sanders, Reinhold Kliegl, József Tollár, Renato Moraes, Urs Granacher
BACKGROUND: Dynamic balance keeps the vertical projection of the center of mass within the base of support while walking. Dynamic balance tests are used to predict the risks of falls and eventual falls. The psychometric properties of most dynamic balance tests are unsatisfactory and do not comprise an actual loss of balance while walking. OBJECTIVES: Using beam walking distance as a measure of dynamic balance, the BEAM consortium will determine the psychometric properties, lifespan and patient reference values, the relationship with selected "dynamic balance tests," and the accuracy of beam walking distance to predict falls...
October 18, 2018: Gerontology
Wilson Barnabas
Brain specific drug delivery is one of the most interesting and challenging areas of research. The blood-brain barrier separates the brain from blood and acts as a barrier to protect the brain from microorganisms, neurotoxins and chemical substances. But, the same mechanism poses an obstacle for the entry of many drugs into the brain. Worldwide, approximately 1.5 billion people are suffering from CNS disorders, such as Parkinson's disease, Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis, stroke, HIV-dementia and others...
October 15, 2018: Journal of Neuroscience Methods
Andrew M Scheidler, Dominique Kinnett-Hopkins, Yvonne C Learmonth, Robert Motl, Citlali López-Ortiz
BACKGROUND: Multiple sclerosis (MS) is a disease of the central nervous system that causes ataxia and deficits in balance. Exercise-based therapies have been identified as integral to the recovery of motor function in MS, but few studies have investigated non-traditional movement interventions. We examined a targeted ballet program (TBP) designed to mitigate ataxia and improve balance in females with mild-to-moderate relapsing-remitting MS. METHODS AND FINDINGS: Twelve females with mild-to-moderate disability due to MS were assessed for study eligibility for the study...
2018: PloS One
Adélia Correia Lúcio, Christiane Boaventura Lourenço, Benito Pereira Damasceno, Maria Helena Baena de Moraes Lopes, Carlos Arturo Levi D'ancona
OBJECTIVE: The aim of this study was to investigate if detrusor overactivity (DO) can be influenced by a pelvic floor muscle (PFM) contraction in multiple sclerosis-associated overactive bladder (MS) and idiopathic overactive bladder (OAB) volunteers and compare urodynamic findings between the two groups. DESIGN: Eighteen women with MS and seventeen women with OAB responded the OAB-V8 questionnaire and performed urodynamic study (UDS) with electromyography of PFM to confirm the presence of a 15-seconds PFM contraction during a DO, when present...
October 18, 2018: American Journal of Physical Medicine & Rehabilitation
Tünde Csépány
The revolutionary progress of research in neuroimmu-nology has led to the introduction of disease modifying therapies in multiple sclerosis at the end of the last century. The International Panel on Diagnosis of Multiple Sclerosis originally proposed the 2001 McDonald criteria to facilitate the diagnosis of MS in patients with the first objective neurological symptom(s) suggesting demyelinating event, when magnetic resonance imaging is integrated with clinical and other paraclinical diagnostic methods. New terms have been introduced to substitute clinical information by MRI: dissemination in space - indicating a multifocal central demyelinating process and dissemination in time - indicating the development of new CNS lesions over time...
September 30, 2018: Ideggyógyászati Szemle
Ülkü Türk Börü, Arda Duman, Ahmet Şükrü Kulualp, Neşe Güler, Mustafa Taşdemir, Ümit Yılmaz, Recep Alp, Cem Bölük
The prevalence of multiple sclerosis (MS) has significantly increased all over the world. Recent studies have shown that Turkey has quite a high prevalence. The aim of this study is to estimate prevalence in the Mediterranean and Black Sea regions of Turkey and to compare the results.This study was designed as a door to door survey in 3 cities. One is located in the Mediterranean region (South), 2 are located in the Black Sea region (North). A previous validated form was used for screening in the field. The patients were examined first in the field, then in the regional health facility...
October 2018: Medicine (Baltimore)
Lauren Strober, John DeLuca, Ralph Hb Benedict, Adam Jacobs, Jeffrey A Cohen, Nancy Chiaravalloti, Lynn D Hudson, Richard A Rudick, Nicholas G LaRocca
BACKGROUND: The need for more robust outcomes in multiple sclerosis (MS) clinical trials has been a main priority of the field for decades. Dissatisfaction with existing measures has led to several consensus meetings and initiatives over the past few decades in hopes of defining and gaining acceptance of measures that are valid, reliable, sensitive to change and progression, and most importantly, relevant to those living with MS. The Multiple Sclerosis Outcome Assessments Consortium (MSOAC) was formed for this purpose...
October 18, 2018: Multiple Sclerosis: Clinical and Laboratory Research
Lindsay O Neto, Elizabeth S Gromisch, Jessica Sloan, Tuula Tyry, Frederick W Foley
PURPOSE: Multiple sclerosis (MS) is a complex, chronic disease that can have debilitating effects on daily activities and well-being, compromising health-related quality of life. One underlying determinant of quality of life (QOL) is perceived illness intrusiveness, which examines the disruptiveness of the condition and/or its related treatment on engagement in interest and activities, in turn affecting psychological functioning. There is evidence that persons with MS (PwMS) have higher level of illness intrusiveness compared to those with other chronic conditions; however, limited research exists on differences by sex...
October 17, 2018: Quality of Life Research
Shogo Tanabe, Yuki Fujita, Kaori Ikuma, Toshihide Yamashita
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system that is characterized by motor deficits, fatigue, pain, cognitive impairment, and sensory and visual dysfunction. Secondary progressive multiple sclerosis (SPMS) is a progressive form of MS that develops from relapsing-remitting MS. Repulsive guidance molecule-a (RGMa) has diverse functions, including axon growth inhibition and immune regulation. Here, we show inhibiting RGMa had therapeutic effects in mouse models of SPMS. We induced experimental autoimmune encephalomyelitis in nonobese diabetic mice (NOD-EAE mice) and treated them with humanized anti-RGMa monoclonal antibody...
October 17, 2018: Cell Death & Disease
Kristen M Krysko, Jennifer Graves, Mary Rensel, Bianca Weinstock-Guttman, Gregory Aaen, Leslie Benson, Tanuja Chitnis, Mark Gorman, Manu Goyal, Lauren Krupp, Timothy Lotze, Soe Mar, Moses Rodriguez, John Rose, Michael Waltz, T Charles Casper, Emmanuelle Waubant
OBJECTIVE: To characterize the use and safety of newer disease-modifying therapies (DMTs) in children with multiple sclerosis (MS) and clinically isolated syndrome (CIS) treated under 18 years of age. METHODS: This is a cohort study including children with MS or CIS followed at 12 outpatient practices participating in the US Network of Pediatric MS Centers. DMT use, including duration, dose, and side effects, was analyzed. Newer DMTs were defined as agents receiving Food and Drug Administration approval or with increased use in adult MS after 2005...
October 17, 2018: Neurology
Ilse Baert, Tori Smedal, Alon Kalron, Kamila Rasova, Adnan Heric-Mansrud, Rainer Ehling, Iratxe Elorriaga Minguez, Una Nedeljkovic, Andrea Tacchino, Peter Hellinckx, Greet Adriaenssens, Gosia Stachowiak, Klaus Gusowski, Davide Cattaneo, Sophie Borgers, Jeffrey Hebert, Ulrik Dalgas, Peter Feys
OBJECTIVE: To determine responsiveness of functional mobility measures, and provide reference values for clinically meaningful improvements, according to disability level, in persons with multiple sclerosis (pwMS) in response to physical rehabilitation. METHODS: Thirteen mobility measures (clinician- and patient-reported) were assessed before and after rehabilitation in 191 pwMS from 17 international centers (European and United States). Combined anchor- and distribution-based methods were used...
October 17, 2018: Neurology
Cláudia Sousa, Mariana Rigueiro-Neves, Telma Miranda, Paulo Alegria, José Vale, Ana Margarida Passos, Dawn Langdon, Maria José Sá
BACKGROUND: The validation of international cognitive batteries in different multiple sclerosis (MS) populations is essential. Our objective was to obtain normative data for the Portuguese population of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) and assess its reliability. METHODS: The BICAMS was applied to 105 MS patients and 60 age, gender and education matched healthy controls (HC). In order to test its reliability, BICAMS was re-administered in a subset of 25 patients after a 7-month interval...
October 17, 2018: BMC Neurology
Tosin Lambe, Rui Duarte, James Mahon, Sarah Nevitt, Janette Greenhalgh, Angela Boland, Sophie Beale, Eleanor Kotas, Joanne McEntee, Ian Pomeroy
As part of the single technology appraisal process, the National Institute for Health and Care Excellence invited Merck to submit evidence for the clinical and cost effectiveness of cladribine tablets (cladribine) for the treatment of relapsing-remitting multiple sclerosis (RRMS). Rapidly evolving severe (RES) and sub-optimally treated (SOT) RRMS were specified by the National Institute for Health and Care Excellence as subgroups of interest. The Liverpool Reviews and Implementation Group at the University of Liverpool was the Evidence Review Group...
October 16, 2018: PharmacoEconomics
Stefan Braune, Sarah Grimm, Philip van Hövell, Ulrich Freudensprung, Fabio Pellegrini, Robert Hyde, Arnfin Bergmann
BACKGROUND: Comparative effectiveness (CE) research allows real-world treatment comparisons using outcome measurements important to physicians/patients. This German NeuroTransData registry-based analysis compared delayed-release dimethyl fumarate (DMF) effectiveness with interferons (IFN), glatiramer acetate (GA), teriflunomide (TERI), or fingolimod (FTY) in patients with relapsing-remitting multiple sclerosis (RRMS) using propensity score matching (PSM). METHODS: Data from registry patients aged ≥ 18 years with RRMS, ≥ 1 relapse, and Expanded Disability Status Scale (EDSS) assessment(s) after index therapy initiation underwent 1:1 PSM to match DMF with comparator populations baseline characteristics...
October 16, 2018: Journal of Neurology
Gordon Mazibrada, Charlotte Sharples, Ines Perfect
Background: Fingolimod is approved for the treatment of highly active relapsing-remitting multiple sclerosis in Europe. There is limited information on its effectiveness and safety in clinical practice within the UK. Objective: To evaluate retrospectively the effectiveness and safety of fingolimod in patients with relapsing-remitting multiple sclerosis who were prescribed fingolimod by UK neurologists within the National Health Service. Methods: This was a multicentre, observational study conducted in the UK...
October 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
Huihuang Huang, Siyu Wang, Tianjun Jiang, Rong Fan, Zheng Zhang, Jinsong Mu, Ke Li, Yonggang Wang, Lei Jin, Fang Lin, Jie Xia, Lijian Sun, Biao Xu, Chengcheng Ji, Jing Chen, Juan Chang, Bo Tu, Bing Song, Chao Zhang, Fu-Sheng Wang, Ruonan Xu
Granulocyte colony-stimulating factor (GM-CSF), produced by CD4+ T cells, has recently been implicated in the pathogenesis of inflammatory diseases, such as multiple sclerosis and juvenile arthritis. However, the role of GM-CSF-producing CD4+ T cells in sepsis remains unknown. This study reports peripheral changes in GM-CSF-producing CD4+ T cells in septic patients and the possible underlying mechanism by which GM-CSF influences the outcome of sepsis. Forty-three septic patients, 20 SIRS patients, and 20 healthy controls were enrolled in this study and followed for 28 days to assess mortality...
October 16, 2018: Cellular & Molecular Immunology
Shirin Jamal Omidi, Guadalupe Fernandez BacaVaca, Nuria Lacuey, Aasef G Shaikh, Michael Morgan, Samden D Lhatoo
Ictal gaze deviation and oculogyric crisis (OGC) can show identical clinical manifestations. We report a case of repeated drug induced OGCs in a 38 year old patient with secondary progressive multiple sclerosis. He was referred to our center for treatment of "intractable" epilepsy manifesting as episodic eye and head deviations with apparent unresponsiveness. In the epilepsy monitoring unit, ten typical spells were captured without epileptiform electroencephalographic correlates, but we discovered chronic exposure to metoclopramide...
October 13, 2018: Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia
Bożena Adamczyk, Dorota Koziarska, Sławomir Kasperczyk, Monika Adamczyk-Sowa
So far little has been known about antioxidant properties of immunomodulatory drugs. The aim of the study was to evaluate the antioxidant status in serum of relapsing-remitting multiple sclerosis (RRMS) patients treated with II-line immunomodulatory therapy compared to de novo diagnosed patients, subjects treated with interferon (IFN) beta and healthy controls. We analyzed the relationships depending on the gender, age, disease duration, the Expanded Disability Status Scale (EDSS), the Annualized Relapse Rate (ARR) and MRI lesions in patients treated with II-line...
October 16, 2018: Free Radical Research
Antonios Danelakis, Theoharis Theoharis, Dimitrios A Verganelakis
Multiple sclerosis (MS) is a chronic disease. It affects the central nervous system and its clinical manifestation can variate. Magnetic Resonance Imaging (MRI) is often used to detect, characterize and quantify MS lesions in the brain, due to the detailed structural information that it can provide. Manual detection and measurement of MS lesions in MRI data is time-consuming, subjective and prone to errors. Therefore, multiple automated methodologies for MRI-based MS lesion segmentation have been proposed. Here, a review of the state-of-the-art of automatic methods available in the literature is presented...
October 5, 2018: Computerized Medical Imaging and Graphics: the Official Journal of the Computerized Medical Imaging Society
Christoph Heesen, Antonio Scalfari, Ian Galea
Delivering prognostic information is a challenging issue in medicine and has been largely neglected in the past. A major reason has been a suspected nocebo effect of pessimistic estimates, although this is largely unproven. Among people with multiple sclerosis (MS), there is a strong unmet need to receive long-term prognostic information. This viewpoint discusses reasons for this blind spot in physicians' attitude, foremost among which is the uncertainty of prognostic estimates. Possible strategies to move forward include tools to identify matching patients from large well-defined databases, to deliver an evidence-based individualized estimate of long-term prognosis, and its confidence interval, in a clinical setting...
October 16, 2018: Multiple Sclerosis: Clinical and Laboratory Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"